- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01539889
Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation
September 30, 2014 updated by: Montreal Heart Institute
Pulmonary hypertension (PH) can be the result of various clinical conditions.
It may be idiopathic or associated with various cardiovascular and lung disorders.
Currently there is no test that can non-invasively detect abnormalities of the pulmonary circulation.
There is a growing need for a non-invasive method to detect PH.
There currently exists only ne agent approved in Canada for clinical imaging of the pulmonary circulation, 99mTc-labeled macroaggregates.
This agent is exclusively used for the diagnosis of physical defects of the circulation due to pulmonary embolus.
This agent is larger than small pulmonary vessels, limiting its sensitivity to detect small vascular defects, as well as potential infectious risks since albumin macroaggregates are derived from human albumin.
There is need then for new lung tracers that could provide a greater safety profile while enabling functional as well as anatomical imaging of the pulmonary circulation.
DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52).
Hence the development of this novel AM derivative, PulmoBind, for molecular imaging of the pulmonary circulation.
PulmoBind is labeled with 99mTc, the most commonly used imaging isotope in nuclear medicine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male or female greater than 18 years of age. Female subjects must be post-menopausal (defined as two years after menstrual cycle)
- within normal range for the following: BP systolic 100-140 mmHg and diastolic 50-90 mmHg;
- HR 60-100 beats per minute;
- oral temperature less than 37.6 degrees Centigrade;
- respiratory rate 12-20 breaths per minute;
- normal lung function tests;
- normal echocardiogram including estimation of pulmonary artery systolic pressure;
- normal chest x-ray; Normal electrocardiogram
Exclusion Criteria:
any known chronic or acute medical condition with or without the need for chronic pharmacologic therapy or any condition that may interfere with normal biodistribution of DFH-12. Includes but not limited to:
- lung parenchymal or lung vascular diseases such as chronic obstructive pulmonary disease,
- bronchitis,
- lung cancer,
- pleural effusion,
- emphysema,
- asthma,
- pulmonary fibrosis,
- occupational lung disease,
- pulmonary hypertension (primary or secondary),
- systemic hypertension,
- diabetes,
- cancer,
- kidney disease,
- liver disease,
- heart failure or previous myocardial infarction,
- coronary artery disease,
- peripheral vascular disease or inflammatory disease;
- subjects requiring chronic administration of any substance for a medical condition, active smoking or history of smoking for more than one year in the past 10 years, known self-reported alcoholism (active or abstinent);
- unable to tolerate study procedures ex.(venipuncture, movement restrictions during imaging);
- previous nuclear study since one week (to avoid cross-contamination)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DFH-12 PulmoBind
DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
|
DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52).
Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium.
3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine optimal dose of PulmoBind to be administered for lung imaging in humans
Time Frame: 48 hours
|
To determine the optimal dose of Pulmobind by evaluating the safety and efficacy in three groups of subjects with 3 different doses of study drug; 5mCi, 10mCi, and 15 mCi.For safety evaluation we will provide pharmacokinetic and biodistribution data following injections of the 3 doses mentioned.
Vital signs, hematology and biochemistry will also be captured for each of the doses up to 24 and 48 hours after injections of PulmoBind.
Furthermore local and systemic reactions 24 hours and 48 hours after injections of PulmoBind will also be captured.
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jocelyn Dupuis, MD, Montréal Heart
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Levac X, Harel F, Finnerty V, Nguyen QT, Letourneau M, Marcil S, Fournier A, Dupuis J. Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs. EJNMMI Res. 2016 Dec;6(1):43. doi: 10.1186/s13550-016-0198-3. Epub 2016 May 27.
- Harel F, Levac X, Nguyen QT, Letourneau M, Marcil S, Finnerty V, Cossette M, Fournier A, Dupuis J. Molecular imaging of the human pulmonary vascular endothelium using an adrenomedullin receptor ligand. Mol Imaging. 2015;14. doi: 10.2310/7290.2015.00003.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
February 22, 2012
First Submitted That Met QC Criteria
February 27, 2012
First Posted (Estimate)
February 28, 2012
Study Record Updates
Last Update Posted (Estimate)
October 1, 2014
Last Update Submitted That Met QC Criteria
September 30, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- The PulmoBind Safety Trial
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on 99mTC-PulmoBind
-
Peking Union Medical College HospitalCompletedBreast CancerChina
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
Temple UniversityWithdrawnVenous ThrombosisUnited States
-
British Columbia Cancer AgencyCanadian Institutes of Health Research (CIHR); Lawson Health Research Institute and other collaboratorsCompleted
-
Peking Union Medical College HospitalCompleted
-
Peking UniversitySun Yat-sen University; China-Japan Union Hospital, Jilin UniversityCompleted
-
Peking Union Medical College HospitalRecruiting
-
Xijing HospitalNot yet recruiting99mTc-FAPI-positive Gastrointestinal Tumor
-
Mayo ClinicRecruitingAortic Stenosis | Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Transthyretin Amyloid CardiomyopathyUnited States
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityPeking UniversityUnknownEsophageal Cancer | Diagnoses Disease | Lymph Node MetastasesChina